Based on these preclinical evidences, a prospective clinical trial combining humanized anti-CD19 CAR T cells with ibrutinib in CLL patients not achieving a CR after 6 months of single-agent ibrutinib treatment is currently ongoing at the UPenn (NCT02640209) (51). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.